Photo of Professor Jamshed Bomanji

Professor Jamshed Bomanji

Telephone:

Email:

GMC/GDC number:

2876984

Professional background

Professor Jamshed Bomanji graduated in 1980. Jamshed did his post-graduation at St Bartholomew’s Hospital where he completed his Masters and PhD in Nuclear Medicine in 1987. He was appointed as consultant in nuclear medicine at St Bartholomew’s Hospital in 1990 and then moved to the Middlesex Hospital in 1993, which is now part of the UCLH NHS Foundation Trust.

Currently, he is the clinical lead and head of department at the Institute of Nuclear Medicine, which is the largest single-site department in UK.

He has contributed and published more than 142 research and clinical papers in peer-reviewed journals, authored 20 book chapters, and is the editor of Nuclear Medicine in Oncology. He is the assistant editor and advisory editor of various journals in the field of nuclear medicine.

He has expertise including diagnostic and therapeutic applications of nuclear medicine techniques in benign and malignant diseases and bringing new diagnostic and therapeutic radiopharmaceuticals into clinical practice for patient benefit.

 

Research interests

All aspects of diagnostic and therapeutic applications of nuclear medicine.

Professor Bomanji is especially  known for research in PET-CT imaging, tuberculosis, and radioligand therapy.

Languages spoken

Urdu, Punjabi, Gujarati

Publications

Some recent publications: 

  • Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009 Dec;50(12):1927-32. 
  • Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK, Kottaridis PD, Roughton M, Morris EC, Goldstone AH, Linch DC, Ell PJ, Mackinnon S. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood. 2010 Apr 8;115(14):2763-8.  
  • Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010 Jun;51(6):875-82.    
  • Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Procedure guidelines for PET/CT tumour imaging with (68)Ga-DOTA-conjugated peptides: (68)Ga-DOTA-TOC, (68)Ga-DOTA-NOC, (68)Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-10.